New Results for ALN-AGT at the ESH-ISH 2021 Joint Meeting

New Results for ALN-AGT at the ESH-ISH 2021 Joint Meeting

Positive results from the ongoing Phase 1 study of ALN-AGT, an investigational RNAi therapeutic for the treatment of hypertension, were presented during the 2021 Joint Meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH). ALN-AGT treatment was associated with dose-dependent knockdown of angiotensinogen (AGT) and reductions in blood pressure (BP), with a durability that supports the potential for a once quarterly or biannual dosing regimen.

Read the press release

View the presentation

  • Patients treated with single doses of ALN-AGT at 100 mg or higher experienced durable reductions in serum AGT of more than 90 percent through 12 weeks.
  • Reductions in 24-hour systolic blood pressure (SBP) of >10 mm Hg were observed at Week 8 after single doses of 100 mg or higher.
  • These durable pharmacologic effects of ALN-AGT may support tonic control of BP with once quarterly and potentially biannual dosing.
  • ALN-AGT was shown to be generally well tolerated with an acceptable safety profile that supports advancement into the Phase 2 KARDIA studies planned in mid-2021.


Receive news and updates on the work at Alnylam that affects you most.